OREX Insider Trading Activity and SEC Form 4 Filings
OREX insider trading summary
No open-market insider purchases or sales of Orexigen Therapeutics, Inc. (OREX) have been reported on SEC Form 4 in the past 12 months.
Latest OREX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 15, 2018 | Stephen A. Moglia | VP & Chief Accounting Officer | Sell | $407 (1,694 @ $0.24) |
| Dec 19, 2016 | Stephen A. Moglia | VP, Chief Accounting Officer | Sell | $2K (800 @ $1.96) |
| Feb 26, 2015 | Mark D Booth | Chief Commercial Officer | Sell | $284K (50,000 @ $5.68) |
| Dec 2, 2014 | Heather D Turner | SVP, Gen. Counsel & Secretary | Sell | $136K (22,643 @ $6.00) |
| Nov 25, 2014 | Heather D Turner | SVP, Gen. Counsel & Secretary | Sell | $44K (7,382 @ $6.00) |
| Nov 24, 2014 | Heather D Turner | SVP, Gen. Counsel & Secretary | Sell | $139K (24,006 @ $5.77) |
| Nov 18, 2014 | Louis C Bock | Director | Buy | $4K (700 @ $5.58) |
| Nov 18, 2014 | Louis C Bock | Director | Buy | $3K (625 @ $5.58) |
| Nov 12, 2014 | Louis C Bock | Director | Buy | $151K (27,052 @ $5.57) |
| Sep 22, 2014 | Heather D Turner | VP, Gen. Counsel & Secretary | Sell | $1.3M (300,000 @ $4.46) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.